Article
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
Therapeutic advances in respiratory disease - 1 Dec 2016
Sullivan Ivana, Planchard David
Abstract excerpt
Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. Unfortunately, the majority of patients develop resistance to them after a median...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.